Javascript must be enabled to continue!
Human fetal pancreatic insulin-producing cells proliferate in vitro
View through CrossRef
There have been considerable efforts towards understanding the potential of human pancreatic endocrine cells to proliferate and transition into mesenchymal cell populations. Since rodent studies have demonstrated that mouse insulin-producing cells do not proliferate
in vitro
, a similar possibility has been considered for human islet endocrine cells. Considering the inherent differences in mouse and human pancreatic islets, we decided to assess the potential of human fetal pancreatic insulin-producing cells to proliferate
in vitro
. We studied the proliferative potential of human fetal pancreatic islet-derived populations from second or third trimester fetal pancreas and characterized the cells that grow out during their expansion. We have used seven different approaches including
in situ
hybridization and immunostaining, quantitative estimation of multiple gene transcripts in populations as well as in single cells, clonal analysis of islet cells, assessment of heritable marks of active insulin promoter, and thymidine analog-based lineage tracing. Our studies demonstrate that human fetal pancreatic insulin-producing cells proliferate
in vitro
to generate mesenchymal cell populations. Interestingly, epigenetic modifications that mark open chromatin conformation of insulin promoter regions are retained even after a million fold expansion/proliferation
in vitro
. These findings demonstrate that hormone-producing cells in pancreatic islets proliferate
in vitro
and retain epigenetic marks that characterize an active insulin promoter. Such
in vitro
-derived mesenchymal cells may be of potential use in cell-replacement therapy for diabetes.
Title: Human fetal pancreatic insulin-producing cells proliferate in vitro
Description:
There have been considerable efforts towards understanding the potential of human pancreatic endocrine cells to proliferate and transition into mesenchymal cell populations.
Since rodent studies have demonstrated that mouse insulin-producing cells do not proliferate
in vitro
, a similar possibility has been considered for human islet endocrine cells.
Considering the inherent differences in mouse and human pancreatic islets, we decided to assess the potential of human fetal pancreatic insulin-producing cells to proliferate
in vitro
.
We studied the proliferative potential of human fetal pancreatic islet-derived populations from second or third trimester fetal pancreas and characterized the cells that grow out during their expansion.
We have used seven different approaches including
in situ
hybridization and immunostaining, quantitative estimation of multiple gene transcripts in populations as well as in single cells, clonal analysis of islet cells, assessment of heritable marks of active insulin promoter, and thymidine analog-based lineage tracing.
Our studies demonstrate that human fetal pancreatic insulin-producing cells proliferate
in vitro
to generate mesenchymal cell populations.
Interestingly, epigenetic modifications that mark open chromatin conformation of insulin promoter regions are retained even after a million fold expansion/proliferation
in vitro
.
These findings demonstrate that hormone-producing cells in pancreatic islets proliferate
in vitro
and retain epigenetic marks that characterize an active insulin promoter.
Such
in vitro
-derived mesenchymal cells may be of potential use in cell-replacement therapy for diabetes.
Related Results
(Invited) A Protein-Based Artificial Receptor for Insulin Sensing
(Invited) A Protein-Based Artificial Receptor for Insulin Sensing
Insulin is one of the most important hormones that controls the glucose level in blood. Therefore, the investigation of insulin is very important for the diabetic research. There h...
Insulin Lispro: Its Role in the Treatment of Diabetes Mellitus
Insulin Lispro: Its Role in the Treatment of Diabetes Mellitus
OBJECTIVE:
To introduce a rapid-acting human insulin analog, insulin lispro; to review its pharmacology, therapeutics, pharmacokinetics, dosing guidelines, adve...
New and simple Ohmic definition of insulin resistance in lean and obese subjects
New and simple Ohmic definition of insulin resistance in lean and obese subjects
objective:: Insulin enhances the influx of glucose into cells. However, the relationship between glucose and insulin is complex and insulin sensitivity varies widely with age, ethn...
3D differentiation enhances the efficiency of differentiation of human induced pluripotent stem cells to insulin producing cells
3D differentiation enhances the efficiency of differentiation of human induced pluripotent stem cells to insulin producing cells
<p>Type 1 Diabetes (T1D) is an autoimmune disorder in which the pancreatic β-cells are destroyed by the body's immune system. The reduced number of β-cells leads to inadequat...
Mutations in Insulin-Receptor Gene in Insulin-Resistant Patients
Mutations in Insulin-Receptor Gene in Insulin-Resistant Patients
Defects in insulin-receptor function have been associated with insulin-resistant states such as obesity and non-insulin-dependent diabetes mellitus (NIDDM). Several types of mutati...
The Dual Effects of Silibinin on Human Pancreatic Cells
The Dual Effects of Silibinin on Human Pancreatic Cells
Objective: Silibinin is a flavonoid with antihepatotoxic properties, and exhibits pleiotropic anticancer effects. However, the molecular mechanisms responsible for its anticancer a...
Effect of intranasal insulin on osteocalcin levels and postoperative delirium in elderly patients undergoing joint replacement
Effect of intranasal insulin on osteocalcin levels and postoperative delirium in elderly patients undergoing joint replacement
Abstract
Background
Recently, intranasal insulin has shown great promise in preventing perioperative neurocognitive disorders t...
Global Policy and Practice for Intrauterine Fetal Resuscitation During Fetal Surgery for Open Spina Bifida Repair
Global Policy and Practice for Intrauterine Fetal Resuscitation During Fetal Surgery for Open Spina Bifida Repair
ImportanceGlobally accepted recommendations suggest that a woman should be between 19 weeks and 25 weeks plus 6 days of pregnancy to be considered eligible for fetal closure of ope...

